You might like
Yesterday we rang the opening bell at the #NewYorkStockExchange, celebrating innovation and collaboration in #HIVscience! @NYSE
ICER in a new report suggests Novartis’ #siponimod, which is used in the treatment of secondary progressive multiple sclerosis, “far exceeds” common #QALY and #LYG cost thresholds. #HEOR #SPMS #ICER #Novartis | ow.ly/4Jr450tWuGl
AMA Study Finds Lack of Health Payer Competition Across US shar.es/aaZ7kd
A recent study found highly-variable times among European countries to reach health technology assessment decisions to reimburse new #cancer treatments approved by the European Medicines Agency. #HEOR #HTA #DrugApprovals | ow.ly/uc8x30mjByZ
Salt, Louis IV, and HEOR: A Focus on Three Trends in Publication Planning ismpp-newsletter.com/2018/09/26/sal…
ismpp-newsletter.com
Salt, Louis IV, and HEOR: A Focus on Three Trends in Publication Planning
Publication professionals work in an industry experiencing a shift in required evidence related to a product’s value, as well as its safety and efficacy. They manage the release of clinical and eco…
Dupilumab (Dupixant®): Follow up Approval in European Union adisintouch.com/2017/10/11/dup…
Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell ca… adisintouch.com/2017/10/11/tiv…
Avelumab (Bavencio®): Follow up Approvals in Europe and Japan adisintouch.com/2017/10/06/ave…
Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis adisintouch.com/2017/08/22/gus…
Scottish Medicines Consortium accepts @Amgen's multiple myeloma Tx KYPROLIS® (carfilzomib), combo with dexamethasone, for use at 1st relapse
Valenta Pharmaceuticals get US FDA CRL for Latanoprostene Bunod solution NDA; No safety or efficacy issues
Independent DMC completes review of Celsion Corporation's Phase III ThermoDox® OPTIMA study in Liver cancer and approves study continuation
Distrust in the EOL care provided to a parent and long-term negative outcomes among bereaved adolescents bit.ly/2wMZMRG #pallonc
FDA warns of potential contamination in multiple brands of drugs, dietary supplements. More information here: go.usa.gov/xRpjp
EMA supports regulatory harmonisation activities in East Africa: bit.ly/2uCfGNe
Cascadian therapeutics gets @EMA_News confirmation for HER2CLIMB study data for tucatinib as sufficient data for MAA in HER2+ breast cancer
Baricitinib (Olumiant™): Follow up Approval in Japan (but not yet USA) adisintouch.com/2017/07/12/bar… #RheumatoidArthritis #RA
Ocular Therapeutics Receives CRL from @US_FDA for DEXTENZA™ NDA citing deficiencies in mfg, analytical processes; No safety/efficacy issues
Durvalumab (Imfinzi™): First Global Approval - immune-stimulation brings hope in #BladderCancer adisintouch.com/2017/07/13/dur… #MetastaticCancer
United States Trends
- 1. #heatedrivalry 95.8K posts
- 2. Rams 79.4K posts
- 3. Rams 79.4K posts
- 4. ilya 85.5K posts
- 5. Puka 53.1K posts
- 6. Sam Darnold 20.8K posts
- 7. svetlana 8,161 posts
- 8. Andrea 28.3K posts
- 9. Stafford 22.4K posts
- 10. Al Michaels 2,926 posts
- 11. #PowerForce 1,580 posts
- 12. SCOTT HUNTER 13.3K posts
- 13. #zzzSpecialProgram 7,029 posts
- 14. Ben Shapiro 49K posts
- 15. Rose 170K posts
- 16. jacob tierney 6,389 posts
- 17. #TSTheEndOfAnEra 11.3K posts
- 18. #zzzero 36K posts
- 19. connor storrie 18.1K posts
- 20. McVay 8,391 posts
Something went wrong.
Something went wrong.